within Pharmacolibrary.Drugs.ATC.N;

model N03AX17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.76,
    Cl             = 9.166666666666667e-05,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00085,
    Tlag           = 900
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N03AX17</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Stiripentol is an antiepileptic drug primarily used as an adjunctive therapy for the treatment of Dravet syndrome, a rare and severe form of childhood epilepsy. It acts mainly through enhancement of GABAergic neurotransmission and inhibition of certain hepatic enzymes. Stiripentol is approved for use in Europe and the USA as an add-on therapy for seizures associated with Dravet syndrome.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following single or multiple oral doses.</p><h4>References</h4><ol><li><p> (2024). Comparison Table: Some oral antiseizure medications. <i>The Medical letter on drugs and therapeutics</i> 66(1708) e133–e140. DOI:<a href=\"https://doi.org/10.58347/tml.2024.1708b\">10.58347/tml.2024.1708b</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39073881/\">https://pubmed.ncbi.nlm.nih.gov/39073881</a></p></li><li><p>Jacob, S, &amp; Nair, AB (2016). An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. <i>Drugs in R&amp;D</i> 16(4) 303–316. DOI:<a href=\"https://doi.org/10.1007/s40268-016-0148-6\">10.1007/s40268-016-0148-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27766590/\">https://pubmed.ncbi.nlm.nih.gov/27766590</a></p></li><li><p>Dai, Q, et al., &amp; Chen, Y (2020). Using Self-Nanoemulsifying System to Improve Oral Bioavailability of a Pediatric Antiepileptic Agent Stiripentol: Formulation and Pharmacokinetics Studies. <i>AAPS PharmSciTech</i> 21(5) 192–None. DOI:<a href=\"https://doi.org/10.1208/s12249-020-01730-z\">10.1208/s12249-020-01730-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32661608/\">https://pubmed.ncbi.nlm.nih.gov/32661608</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N03AX17;
